|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
9 p, 707.5 KB |
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
/
Christodoulou, M. (The Christie NHS Foundation Trust) ;
Blackhall, Fiona (University of Manchester) ;
Mistry, H. (University of Manchester) ;
Leylek, A. (CancerCare Manitoba) ;
Knegjens, J. (The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital) ;
Remouchamps, V. (CHU UCL Namur. site Ste Elisabeth) ;
Martel-Lafay, I. (Centre Léon Bérard) ;
Farré, Núria (Institut d'Investigació Biomèdica Sant Pau) ;
Zwitter, M. (Institute of Oncology) ;
Lerouge, D. (Centre François Baclesse (Caen, França)) ;
Pourel, N. (Institut Sainte-Catherine) ;
Janicot, H. (CHU Gabriel Montpied) ;
Scherpereel, A. (Hospital of the University (CHRU) of Lille) ;
Tissing-Tan, C. (Radiotherapiegroep) ;
Peignaux, K. (Georges Francois LECLERC Center) ;
Geets, X. (Cliniques universitaires Saint-Luc. MIRO-IREC-UCL) ;
Konopa, K. (Medical University of Gdansk) ;
Faivre-Finn, C. (University of Manchester)
There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited-stage, patients with SCLC. We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once-daily Versus twice-daily RadioTherapy (CONVERT) trial. [...]
2019 - 10.1016/j.jtho.2018.09.027
Journal of Thoracic Oncology, Vol. 14 Núm. 1 (january 2019) , p. 63-71
|
|
|
3.
|
|
14 p, 425.7 KB |
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC : Primary and Correlative Biomarker Analyses
/
Owonikoko, Taofeek K. (Winship Cancer Institute of Emory University) ;
Niu, Huifeng (Millennium Pharmaceuticals. Inc.) ;
Nackaerts, Kristiaan (KU Leuven. Universitaire Ziekenhuizen) ;
Csoszi, Tibor (Hetenyi G Korhaz) ;
Ostoros, Gyula (Orszagos Koranyi TBC es Pulmonologiai Intezet) ;
Mark, Zsuzsanna (Tudogyogyintezet Torokbalint) ;
Baik, Christina (University of Washington Seattle Cancer Care Alliance) ;
Joy, Anil Abraham (University of Alberta. Cross Cancer Institute) ;
Chouaid, Christos (CHI de Créteil) ;
Jaime, Jesus Corral (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Kolek, Vitezslav (Fakultni Nemocnice Olomouc) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Roubec, Jaromir (Fakultni Nemocnice Ostrava) ;
Santos, Edgardo S. (Lynn Cancer Institute/Boca Raton Regional Hospital) ;
Chiang, Anne C. (Yale University School of Medicine) ;
Speranza, Giovanna (Université de Sherbrooke) ;
Belani, Chandra P. (Penn State Cancer Institute) ;
Chiappori, Alberto (H. Lee Moffitt Cancer Center) ;
Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ;
Czebe, Krisztina (Tudogyogyintezet Torokbalint) ;
Byers, Lauren (Tudogyogyintezet Torokbalint) ;
Bahamon, Brittany (Millennium Pharmaceuticals. Inc.) ;
Li, Cong (Millennium Pharmaceuticals. Inc.) ;
Sheldon-Waniga, Emily (Millennium Pharmaceuticals. Inc.) ;
Kong, Eric F. (University of Texas M. D. Anderson Cancer Center) ;
Williams, Miguel (Millennium Pharmaceuticals. Inc.) ;
Badola, Sunita (Millennium Pharmaceuticals. Inc.) ;
Shin, Hyunjin (Millennium Pharmaceuticals. Inc.) ;
Bedford, Lisa (Millennium Pharmaceuticals. Inc.) ;
Ecsedy, Jeffrey A. (Millennium Pharmaceuticals. Inc.) ;
Bryant, Matthew (University of Texas M. D. Anderson Cancer Center) ;
Jones, Sian (University of Texas M. D. Anderson Cancer Center) ;
Simmons, John (University of Texas M. D. Anderson Cancer Center) ;
Leonard, E. Jane (Millennium Pharmaceuticals. Inc.) ;
Ullmann, Claudio Dansky (Millennium Pharmaceuticals. Inc.) ;
Spigel, David R. (Personal Genome Diagnostics) ;
Universitat Autònoma de Barcelona
We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC. In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant or refractory) and brain metastases and randomized 1:1 to alisertib/paclitaxel or placebo plus paclitaxel (henceforth referred to as placebo/paclitaxel) in 28-day cycles. [...]
2020 - 10.1016/j.jtho.2019.10.013
Journal of Thoracic Oncology, Vol. 15 Núm. 2 (february 2020) , p. 274-287
|
|
|
4.
|
|
12 p, 339.3 KB |
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC : Results From the Phase 3 TAHOE Study
/
Blackhall, Fiona (Department of Medical Oncology. The Christie National Health Service (NHS) Foundation Trust) ;
Jao, K. (Department of Hematology and Oncology. Hopital du Sacre Coeur Montreal) ;
Greillier, L. (Multidisciplinary Oncology and Therapeutic Innovations Department. Centre de Recherche en Cancérologie de Marseille (CRCM). Centre National de la Recherche Scientifique (CNRS). Institut National de la Santé et de la Recherche Médicale (INSERM). Assistance Publique-Hopitaux de Marseille (APHM). Aix-Marseille University) ;
Cho, B.C. (Division of Medical Oncology. Department of Internal Medicine. Yonsei Cancer Center. Yonsei University College of Medicine) ;
Penkov, K. (Private Medical Institution Euromedservice) ;
Reguart, Noemi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Nackaerts, K. (Department of Pulmonology and Respiratory Oncology. University Hospital Leuven. Katholieke Universiteit (KU) Leuven) ;
Syrigos, K. (Department of Medicine. National and Kapodistrian University of Athens) ;
Hansen, K. (Odense University Hospital (Dinamarca)) ;
Schuette, W. (2nd Medical Department. Krankenhaus Martha-Maria Halle-Doelau. Halle) ;
Cetnar, J. (Department of Medicine. Oregon Health & Science University) ;
Cappuzzo, F. (Department of Medical Oncology. Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)) ;
Okamoto, I. (Department of Medical Oncology. Kyushu University Hospital) ;
Erman, M. (Department of Medical Oncology. Cancer Institute. Hacettepe University) ;
Langer, S.W. (Rigshospitalet. University of Copenhagen) ;
Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ;
Groen, H. (Department of Pulmonary Disease. University Medical Center Groningen. University of Groningen) ;
Sun, Z. (AbbVie. Inc.) ;
Luo, Y. (AbbVie. Inc.) ;
Tanwani, P. (AbbVie. Inc.) ;
Caffrey, L. (AbbVie. Inc.) ;
Komarnitsky, P. (AbbVie. Inc.) ;
Reinmuth, N. (Thoracic Oncology Department. Asklepios Fachkliniken München-Gauting)
Introduction: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. [...]
2021 - 10.1016/j.jtho.2021.02.009
Journal of Thoracic Oncology, Vol. 16 Núm. 9 (september 2021) , p. 1547-1558
|
|
|
5.
|
|
15 p, 598.6 KB |
Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC
/
Herbst, Roy S (Section of Medical Oncology. Yale Comprehensive Cancer Center. Yale University School of Medicine) ;
Garon, E.B. (David Geffen School of Medicine. University of California Los Angeles) ;
Kim, D.W. (Seoul National University Hospital. Seoul National University College of Medicine) ;
Cho, B.C. (Yonsei Cancer Center. Yonsei University College of Medicine) ;
Gervais, R. (Centre François Baclesse (Caen, França)) ;
Perez-Gracia, J.L. (Clínica Universidad de Navarra) ;
Han, J.Y. (Center for Lung Cancer. National Cancer Center) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Forster, M.D. (UCL Cancer Institute/University College London Hospitals) ;
Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ;
Novello, Silvia (Department of Oncology. University of Turin. Azienda Ospedaliero Universitaria San Luigi) ;
Gubens, M.A. (University of California. San Francisco) ;
Boyer, M. (Chris O'Brien Lifehouse) ;
Su, W.C. (National Cheng Kung University Hospital) ;
Samkari, A. (Merck & Co.. Inc.) ;
Jensen, E.H. (Merck & Co.. Inc.) ;
Kobie, J. (Merck & Co.. Inc.) ;
Piperdi, B. (Merck & Co.. Inc.) ;
Baas, Pieter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Introduction: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. [...]
2021 - 10.1016/j.jtho.2021.05.001
Journal of Thoracic Oncology, Vol. 16 Núm. 10 (october 2021) , p. 1718-1732
|
|
|
6.
|
|
13 p, 1.0 MB |
Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT : An Exploratory Study
/
Kim-Wanner, S. Z. (German Red Cross Blood Donor Service. Institute of Transfusion Medicine and Immune Hematology of the Goethe University Medical School) ;
Assenov, Y. (Division of Epigenomics. German Cancer Research Center (Deutsches Krebsforschungszentrum [DKFZ])) ;
Nair, M. B. (Division of Epigenomics. German Cancer Research Center (Deutsches Krebsforschungszentrum [DKFZ])) ;
Weichenhan, D. (Division of Epigenomics. German Cancer Research Center (Deutsches Krebsforschungszentrum [DKFZ])) ;
Benner, Axel (Division of Biostatistics. German Cancer Research Center (DKFZ)) ;
Becker, N. (Division of Biostatistics. German Cancer Research Center (DKFZ)) ;
Landwehr, K. (German Red Cross Blood Donor Service. Institute of Transfusion Medicine and Immune Hematology of the Goethe University Medical School) ;
Kuner, R. (Translational Oncology at the University Medical Center of Johannes Gutenberg University) ;
Sültmann, H. (Translational Lung Research Centre Heidelberg. Member of the German Centre for Lung Research (Deutsches Zentrum für Lungenforschung)) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koch, I. (Center of Thoracic Surgery. Asklepios Fachkliniken München-Gauting. Ludwig Maximilians University. Gauting; Comprehensive Pneumology Centre Munich. German Centre for Lung Research (Deutsches Zentrum für Lungenforschung)) ;
Lindner, M. (Center of Thoracic Surgery. Asklepios Fachkliniken München-Gauting. Ludwig Maximilians University. Gauting; Comprehensive Pneumology Centre Munich. German Centre for Lung Research (Deutsches Zentrum für Lungenforschung)) ;
Meister, M. (Translational Research Unit. Thoraxklinik at University Hospital Heidelberg) ;
Thomas, M. (Translational Research Unit. Thoraxklinik at University Hospital Heidelberg) ;
Bieg, M. (Division of Theoretical Bioinformatics. and Heidelberg Center for Personalized Oncology. German Cancer Research Center (DKFZ)) ;
Klingmüller, U. (Division Systems Biology of Signal Transduction. German Cancer Research Center (DKFZ)) ;
Schlesner, M. (Bioinformatics and Omics Data Analytics. German Cancer Research Center (DKFZ)) ;
Warth, A. (Heidelberg University Hospital (Alemanya)) ;
Brors, Benedikt (Division of Applied Bioinformatics. German Cancer Research Center (DKFZ)) ;
Seifried, E. (German Red Cross Blood Donor Service. Institute of Transfusion Medicine and Immune Hematology of the Goethe University Medical School) ;
Bönig, H. (German Red Cross Blood Donor Service. Institute of Transfusion Medicine and Immune Hematology of the Goethe University Medical School) ;
Plass, C. (Translational Lung Research Centre Heidelberg. Member of the German Centre for Lung Research (Deutsches Zentrum für Lungenforschung)) ;
Risch, A. (Universität Salzburg. Cancer Cluster Salzburg) ;
Muley, T. (Translational Research Unit. Thoraxklinik at University Hospital Heidelberg) ;
Universitat Autònoma de Barcelona
Introduction: Surgical procedure is the treatment of choice in early stage I lung adenocarcinoma. However, a considerable number of patients experience recurrence within the first 2 years after complete resection. [...]
2020 - 10.1016/j.jtho.2020.03.023
Journal of Thoracic Oncology, Vol. 15 Núm. 8 (august 2020) , p. 1338-1350
|
|
|
7.
|
|
13 p, 2.1 MB |
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study
/
Conde, Esther (Hospital Universitario HM Sanchinarro (Madrid)) ;
Hernández, Susana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Martinez, Rebeca (Hospital Universitario HM Sanchinarro (Madrid)) ;
Angulo, Bárbara (Hospital Universitario HM Sanchinarro (Madrid)) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid)) ;
Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Jimenez, Beatriz (Hospital Universitario HM Sanchinarro (Madrid)) ;
Muriel, Alfonso (Hospital Universitario Ramón y Cajal (Madrid)) ;
Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aranda, Ignacio (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Massuti, Bartomeu (Instituto de Investigación Sanitaria y Biomédica de Alicante) ;
Rojo, Federico (Centro de Investigación Biomédica en Red de Cáncer) ;
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Garcia, Felip (Quironsalud Hospital) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Mancheño, Nuria (Hospital Universitari i Politècnic La Fe (València)) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ;
Sanz, Julián (Hospital Clínico San Carlos (Madrid)) ;
Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ;
Atienza-Cuevas, Lidia (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Arriola-Arellano, Esperanza (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Abdulkader, Ihab (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Garcia-Gonzalez, Jorge (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Camacho, Carmen (Insular Materno-Infantil University Hospital Complex) ;
Rodríguez-Abreu, Delvys (Insular Materno-Infantil University Hospital Complex) ;
Teixidó, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Gonzalez-Piñeiro, Ana (Hospital Álvaro Cunqueiro (Vigo)) ;
Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo)) ;
Lozano, María Dolores (Clínica Universidad de Navarra) ;
Gurpide, Alfonso (Clínica Universidad de Navarra) ;
Gómez-Román, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Lopez-Brea, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ;
Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
Company, Amparo (Hospital Clínic Universitari (València)) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Esteban-Rodriguez, Isabel (Hospital Universitario La Paz (Madrid)) ;
Saiz, Mónica (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Azkona, Eider (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Álvarez, Ramiro (Hospital Universitario Miguel Servet (Saragossa)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Plaza, María Luz (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Aguiar de Sousa, Diana (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Enguita, Ana Belén (Hospital Universitario 12 de Octubre (Madrid)) ;
Benito, Amparo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ;
Lopez-Rios, Fernando (Hospital Universitario HM Sanchinarro (Madrid)) ;
Universitat Autònoma de Barcelona
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. [...]
2019 - 10.1016/j.jtho.2019.07.005
Journal of Thoracic Oncology, Vol. 14 Núm. 12 (december 2019) , p. 2120-2132
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
